Innoviva, Inc.

INVA

US45781M1018

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
15.79 ^USD	+2.87%		+0.06%	-1.56%

May. 20	Zai Lab, Innoviva Subsidiary Receive China Approval for Hospital Infection Treatment	MT
May. 15	Transcript : Innoviva, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 09:20 AM

Tranche Update on Innoviva, Inc.'s Equity Buyback Plan announced on November 9, 2022.

February 29, 2024 at 05:01 pm EST

From October 1, 2023 to December 31, 2023, the company has repurchased 1,121,835 shares, representing 1.86% for $15.39 million. With this, the company has completed the repurchase of 6,820,959 shares, representing 10.22% for $84.36 million under the buyback announced on November 9, 2022.

Latest news about Innoviva, Inc.

Zai Lab, Innoviva Subsidiary Receive China Approval for Hospital Infection Treatment	May. 20	MT
Transcript : Innoviva, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 09:20 AM	May. 15
Earnings Flash (INVA) INNOVIVA Posts Q1 Revenue $77.5M	May. 08	MT
Tranche Update on Innoviva, Inc.'s Equity Buyback Plan announced on November 9, 2022.	May. 08	CI
Innoviva, Inc. Appoints Derek Small to the Board of Directors	May. 08	CI
Innoviva, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Innoviva, Inc.'s Equity Buyback announced on November 9, 2022, has closed with 7,807,887 shares, representing 11.78% for $100 million.	Apr. 24	CI
Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc.?s Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024	Apr. 24	CI
Armata Pharmaceuticals Secures $35 Million Credit Agreement From Innoviva Unit	Mar. 04	MT
North American Morning Briefing : Stock Futures -2-	Mar. 04	DJ
Tranche Update on Innoviva, Inc.'s Equity Buyback Plan announced on November 9, 2022.	Feb. 29	CI
Earnings Flash (INVA) INNOVIVA Reports Q4 Revenue $85.8M	Feb. 29	MT
Innoviva, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 29	CI
Innoviva, Inc. Appoints David Altarac as Chief Medical Officer of Innoviva Specialty Therapeutics	Feb. 06	CI
Innoviva Insider Sold Shares Worth $153,810, According to a Recent SEC Filing	Nov. 17	MT
Tranche Update on Innoviva, Inc.'s Equity Buyback Plan announced on November 9, 2022.	Nov. 01	CI
Innoviva, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 01	CI
Earnings Flash (INVA) INNOVIVA Posts Q3 Revenue $67.3M	Nov. 01	MT
Innoviva Names Stephen Basso as Finance Chief	23-08-28	MT
Innoviva, Inc. Appoints Stephen Basso as Chief Financial Officer	23-08-25	CI
Tranche Update on Innoviva, Inc.'s Equity Buyback Plan announced on November 9, 2022.	23-08-02	CI
Earnings Flash (INVA) INNOVIVA Reports Q2 Revenue $81M	23-08-02	MT
Innoviva, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-02	CI
Innoviva, Inc. Announces Resignation of Deborah L. Birx as Member of the Board of Directors and Chair of the Audit Committee	23-07-11	CI
Innoviva, Inc.(NasdaqGS:INVA) added to Russell Small Cap Comp Value Index	23-06-23	CI

Chart Innoviva, Inc.

Duration

Period

More charts

Company Profile

Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. The Company's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO ELLIPTA. The Company's products include GIAPREZA and XERAVA. GIAPREZA (angiotensin II) injection is approved by the United States Food and Drug Administration (FDA) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. XERAV (eravacycline) for injection is approved by the United States FDA and Singapore Health Sciences Authority (HSA) as a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI).

Sector

Pharmaceuticals

Calendar

2024-07-23 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Innoviva, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

15.79 USD

Average target price

16 USD

Spread / Average Target

+1.33%

Consensus

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
INNOVIVA, INC.	-1.56%	986M
ELI LILLY AND COMPANY	+40.73%	739B
NOVO NORDISK A/S	+32.83%	598B
JOHNSON & JOHNSON	-6.30%	353B
MERCK & CO., INC.	+15.15%	318B
ABBVIE INC.	+4.05%	285B
ASTRAZENECA PLC	+15.00%	240B
NOVARTIS AG	+9.78%	210B
ROCHE HOLDING AG	-5.52%	206B
AMGEN INC.	+6.17%	164B

Other Pharmaceuticals

Innoviva, Inc.

Equities

INVA

US45781M1018

Pharmaceuticals

Tranche Update on Innoviva, Inc.'s Equity Buyback Plan announced on November 9, 2022.